AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 231 min read$EVAX

Evaxion A/S (EVAX) Posts 3-Year EVX-01 Data: 89% Target Precision, Durable Responses

Evaxion A/S reported 3-year phase 2 data for EVX-01 in advanced melanoma, showing 89% target precision, immune responses in all patients, and no tumor progression in monotherapy patients. The data will be presented at ESMO 2026. According to the company, the results support its AI-Immunology platform and EVX-01's potential efficacy.

Original reporting
tradingview.com
Published Oct 23, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 6:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evaxion A/S (EVAX) Posts 3-Year EVX-01 Data: 89% Target Precision, Durable Responses — source image
Source · tradingview.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The three‑year durability data provides a strong de‑risking signal, potentially prompting re‑rating by analysts.

02

Market read

First disclosure of extended Phase 2 results; likely to influence EVAX price and peer valuations.

03

What to watch

Cash runway into H2 2027 reduces financing risk, but upcoming larger trials could dilute short‑term upside

Relevance 8/10Novelty 8/10Timing: after poster session on Oct 24, 2026

Background

Evaxion A/S is a Danish biotech focused on AI‑based neoantigen vaccines; EVX-01 is its lead melanoma candidate.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion released new three-year Phase 2 data for its EVX-01 melanoma vaccine showing 89% target precision and durable T‑cell responses.

Expected impact

likely upward pressure as investors price in improved efficacy signals

Evidence & confidence

Phase 2 durability data is a material catalyst for biotech stocks; no prior public release of these three‑year results.

Market effects

Sector

strengthens confidence in AI‑driven immunotherapy platforms, may benefit peer biotech firms

Regional

European biotech sector could see modest uplift

Global

adds to broader narrative of cancer vaccine advancements

Counterpoint

What could challenge this read

Data may not translate to later‑stage trials; investors should watch for regulatory path clarity

Key entities

  • company
    Evaxion A/S

    Developer of the EVX-01 vaccine platform

Read at source← All news

StoryEvaxion reports three-year durability and immune data for melanoma vaccine

Also covered by

1 outlet

Related articles

OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min
OCT 19
$EVAXHighAI 8/10

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion AS ADR (EVAX) shares rose 21.6% after reporting 3-year data from its EVX-01 phase 2 trial in advanced melanoma patients. All patients maintained clinical responses with no tumor progression. The data will be presented at ESMO Congress 2026. EVX-01 is a personalized cancer vaccine developed using AI-Immunology platform.

investing.com2 min
OCT 19
$EVAXMedAI 8/10

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported sustained clinical responses for all patients at three-year follow-up in a phase 2 trial for its personalized cancer vaccine EVX-01 in advanced melanoma. The data, to be presented at ESMO 2026, showed a 75% objective response rate with 25% of patients achieving complete response. EVX-01 will be discussed in a webinar and poster session.

finanznachrichten.de2 min
OCT 19
$EVAXMedAI 8/10

Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma

Evaxion A/S reported that patients in a Phase 2 study of its personalized cancer vaccine EVX-01 for advanced melanoma maintained responses for three years, with no tumor progression. The company will present the data at ESMO 2026, showing a 75% response rate and 92% clinical benefit at two years. EVX-01 is currently in development for advanced solid tumors. EVAX stock closed at $2.83 on October 16, 2026, and is up 2.83% in pre-market trading.

rttnews.com2 min